STOCK TITAN

Bolt Biotherapeutics Inc - BOLT STOCK NEWS

Welcome to our dedicated news page for Bolt Biotherapeutics (Ticker: BOLT), a resource for investors and traders seeking the latest updates and insights on Bolt Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bolt Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bolt Biotherapeutics's position in the market.

Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) reports positive progress in Phase 2 studies for BDC-1001 and successful safety assessments for BDC-3042. The company's cash balance of $128.6 million as of December 31, 2023, is expected to fund key milestones through late 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) to present company overview at TD Cowen 44th Annual Healthcare Conference, offering insights into novel cancer immunotherapies. The presentation will be live webcasted on Bolt's website with replays available for 30 days post-event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
conferences
-
Rhea-AI Summary
Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) announced the dosing of the first patient in the Phase 2 clinical trial investigating BDC-1001, a HER2-targeting Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC), as a single agent and in combination with the HER2-targeting antibody pertuzumab. The trial aims to evaluate the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of BDC-1001 in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab deruxtecan (Enhertu®). The addition of pertuzumab has been shown to improve anti-tumor efficacy in preclinical models, offering new treatment options for patients with HER2-positive breast cancer. A poster detailing the trial design and rationale will be presented at the 2023 San Antonio Breast Cancer Symposium on December 6, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.75%
Tags
Rhea-AI Summary
BOLT: Bolt Biotherapeutics Reports Positive Clinical Data and Financial Results, Receives FDA Orphan Drug Designation for BDC-1001 in Gastric Cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics (Nasdaq: BOLT) will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Nov. 14, 2023. The presentation will be available via live webcast on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
conferences
-
Rhea-AI Summary
Bolt Biotherapeutics presents updated data from its Phase 1 dose-escalation trial of BDC-1001 at ESMO 2023 Congress. Improved efficacy observed with one complete response and two long-term stable diseases. BDC-1001 continues to be well tolerated.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.77%
Tags
Rhea-AI Summary
Bolt Biotherapeutics to present preclinical data on combination therapy at SITC 38th Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
conferences
-
Rhea-AI Summary
Bolt Biotherapeutics announces dosing of first patient in Phase 1/2 clinical study of BDC-3042 for the treatment of various cancers
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.96%
Tags
-
Rhea-AI Summary
Bolt Biotherapeutics receives FDA Orphan Drug Designation for BDC-1001 in gastric cancer, including gastroesophageal junction cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.97%
Tags
Rhea-AI Summary
Bolt Biotherapeutics receives patent for BDC-3042 immunotherapy, positive for stock
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.77%
Tags
none
Bolt Biotherapeutics Inc

Nasdaq:BOLT

BOLT Rankings

BOLT Stock Data

43.85M
21.16M
3.94%
59.55%
5.17%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Redwood City

About BOLT

bolt biotherapeutics is a start-up with compelling technology from dr. engleman’s lab at stanford university, which demonstrated complete cures in numerous cancer models. the company is backed by strong life sciences investors and is early in its growth curve, seeking bright, highly motivated individuals that will be the company’s future leaders to help it further develop and bring to patients novel and curative biotherapies.